Apricus Biosciences Announces Appointment of Wendell Wierenga, Ph.D., to Board
SAN DIEGO, March 10, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
(Nasdaq:APRI), today announced the appointment of Wendell Wierenga, Ph.D., to
the Company's Board of Directors. Dr. Wierenga brings decades of experience
heading research and development programs that led to the marketing approval
of over 15 medicines and has participated in the filing of over 70
Investigational New Drug (IND) disclosures. His appointment is effective
"We are extremely pleased to add an outstanding, highly qualified scientific
and business leader to our Board," said Kleanthis G. Xanthopoulos, Ph.D.,
Chairman of the Board."We believe Wendell's expertise and demonstrated
success will contribute greatly to our continued progress anticipated in 2014,
including the advancement of our development pipeline based on formulations of
alprostadil and our proprietary DDAIP transdermal delivery platform."
Dr. Xanthopoulos added, "We are also announcing today that Board member
Leonard Oppenheim will not seek re-election at our upcoming annual meeting in
May.I want to personally thank Len for his many contributions over the years,
including his critical guidance during our recent refocusing of the Company on
targeted applications in men's and women's health."
Dr. Wierenga stated, "I am very excited to join the Apricus Board during a
period that is transformative, both in terms of the pending commercial launch
of the Company's lead product, Vitaros^®, through its partners in Europe, and
in regard to the advancement of pipeline products that may have a profound
impact on patient care."
Dr. Wierenga has four decades of experience in research, drug discovery and
drug development, including clinical research, regulatory affairs,
manufacturing, safety, and medical affairs.Most recently, Dr. Wierenga served
as Executive Vice President of Research and Development at Santarus, Inc.,
until the company's $2.6 B acquisition by Salix Pharmaceuticals.Prior to
this, he held the position of Executive Vice President of R&D at Neurocrine
Biosciences and then at Ambit Biosciences.Previously, he was CEO of Syrrx,
Inc., and prior to this held senior positions at Parke-Davis/Warner Lambert
(now Pfizer), including Senior Vice President of Research, R&D and ultimately
Pharmaceutical Technologies. Earlier, Wierenga served at Upjohn
Pharmaceuticals for 16 years, attaining the position of Executive Director of
During his career, Dr. Wierenga led or participated in more than 70
Investigational New Drug disclosures, more than 15 New Drug Applications, and
16 marketed products, including Lipitor^®, Neurontin^®, Lyrica^®, and
Uceris^®. He is on the Scientific Advisory Boards of Concert Pharmaceuticals,
Ferring Pharmaceuticals, and aTyr Pharma, Inc., and currently serves on the
Boards of Directors of Cytokinetics, Inc., and XenoPort, Inc., as well as
having served on several other Boards, including Onyx Pharmaceuticals. Dr.
Wierenga earned his Ph.D. degree in chemistry from Stanford University and his
B.A. degree in chemistry from Hope College.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI), is a pharmaceutical company that develops
and markets through its licensing partners innovative treatments that have the
potential to help large patient populations across numerous, large-market
therapeutic classes including male and female sexual health. The Company has
one approved product, Vitaros^®, for the treatment of erectile dysfunction,
which is now approved in Europe and Canada and will be commercialized by
Apricus' marketing partners, which include Abbott Laboratories Limited, Takeda
Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati S.p.A.,
Bracco SpA and Laboratoires Majorelle. Femprox^®, the Company's product
candidate for the treatment of female sexual interest/arousal disorder, has
successfully completed a nearly 400-subject proof-of-concept study. The
Company is currently seeking a strategic partner for Femprox.
For further information on Apricus, visit http://www.apricusbio.com.
Statements under the Private Securities Litigation Reform Act, as amended:
with the exception of the historical information contained in this release,
the matters described herein contain forward-looking statements that involve
risks and uncertainties that may individually or mutually impact the matters
herein described for a variety of reasons that are outside the control of the
Company, including, but not limited to, its ability to further develop its
product Vitaros^® for ED, such as the room temperature version of Vitaros^®
and product candidate Femprox^® for female sexual interest/arousal disorder
among others; to have its product and product candidates receive additional
patent protection and be approved by relevant regulatory authorities in
Europe, the United States, Canada and in other countries, such as additional
national phase approvals for Vitaros^® in the remaining CMS territories, Spain
and Luxembourg; to successfully commercialize such product and product
candidates and other NexACT^® product candidates and drug delivery technology;
and to achieve its other development, commercialization and financial goals,
such as successfully manufacturing and launching Vitaros^® in partnered
territories. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the
risk factors set forth in the Company's most recent annual report on Form
10-K, as amended, subsequent quarterly reports filed on Form 10-Q, as amended,
and other filings made with the SEC. Copies of these reports are available
from the SEC's website or without charge from the Company.
CONTACT: Steve Martin
Chief Financial Officer
Senior Vice President
Press spacebar to pause and continue. Press esc to stop.